CPMV Mosaic ImmunoEngineering
Patriot Scientific Corp. is a intellectual property licensing company with several patents, which design and development of microprocessor chips design. Its technologies are used in computers, cameras, printers, automotive and industrial devices. The company was founded on June 10, 1987 and is headquartered in Carlsbad, CA.
Company profile
Ticker
CPMV, PTSC
Exchange
Website
CEO
Carlton Johnson
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Exelixis ...
Former names
PATRIOT SCIENTIFIC CORP
SEC CIK
Corporate docs
IRS number
841070278
CPMV stock data
()
Press releases
Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering's Lead Intratumoral Immunotherapy Candidate, MIE-101
29 Jun 21
Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting
28 Jun 21
Mosaic ImmunoEngineering Inc. Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors
15 Jun 21
Investment data
Securities sold
Number of investors
Calendar
5 May 21
2 Aug 21
31 Dec 21
Financial summary
Quarter (USD) |
Mar 21 | Nov 20 | Aug 20 | May 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
May 20 | May 19 | May 18 | May 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 210K | 210K | 210K | 210K | 210K | 210K |
| Cash burn (monthly) | 67.51K | 59.67K | 268.15K | 138.28K | 56.79K | 45.04K |
| Cash used (since last report) | 275.89K | 243.87K | 1.1M | 565.11K | 232.09K | 184.09K |
| Cash remaining | -65.89K | -33.87K | -885.86K | -355.11K | -22.09K | 25.91K |
| Runway (months of cash) | -1.0 | -0.6 | -3.3 | -2.6 | -0.4 | 0.6 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 May 21 | Gloria Felcyn | Convertible Note [object Object] | Other | Aquire J | Yes | No | 25000 | - | 25K | - |
| 7 May 21 | Robert L Garnick | Convertible Note [object Object] | Other | Aquire J | No | No | 100000 | - | 100K | - |
| 29 Apr 21 | Nicole Franziska Steinmetz | RSU Common Stock | Grant | Aquire A | No | No | 2.8 | 5,357 | 15K | 5,357 |
| 29 Jan 21 | Nicole Franziska Steinmetz | Common Stock | Conversion | Aquire C | Yes | No | 0 | 570,870 | 0 | 570,870 |
| 29 Jan 21 | Nicole Franziska Steinmetz | Common Stock | Conversion | Aquire C | No | No | 0 | 1,641,252 | 0 | 1,641,252 |
| 29 Jan 21 | Nicole Franziska Steinmetz | Series A Convertible Voting Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 56,000 | 0 | 0 |
| 29 Jan 21 | Nicole Franziska Steinmetz | Series A Convertible Voting Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 161,000 | 0 | 0 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
|---|---|
| Total holders | 1 |
| Opened positions | 1 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 4.01B |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Western Reserve University Case | 4.01B | $0 |
Financial report summary
?Management Discussion
- Selling, general and administrative expenses increased from $734,062 for the fiscal year ended May 31, 2019 to $996,019 for the fiscal year ended May 31, 2020. The current fiscal year increase in expenses was primarily due to higher compensation expense mostly associated with severance expense paid to Mr. Flowers, our former Chief Financial Officer. Mr. Flowers resigned on September 30, 2019 and agreed to severance compensation of $327,750, in lieu of any amounts owed under his amended and restated employment agreement, payable in seven equal monthly installments commencing October 30, 2019. In addition, during the current fiscal year, we had an increase in consulting fees, mostly associated with the evaluation of new business opportunities in collaboration with Artius Bioconsulting LLC. These current fiscal year increases in expenses were offset by lower board fees as our board member volunteered to cease taking board fees.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
altering, attack, bid, called, deferral, Dr, earliest, effector, EPO, examination, exceed, Fiering, float, freezing, goal, injected, innate, microenvironment, Nicole, OTCQB, plant, profile, promise, reduction, refrigeration, regularly, requalify, secondary, sector, shareholder, showing, Simplifying, sought, spouse, Steinmetz, Steve, strong, sum, superior, thereon, tier, titled, Trademark, unrecognized, unvested, vitro
Removed:
affiliated, aforementioned, annually, annum, approximate, caption, classification, comparability, continuing, derecognition, description, determination, direct, disclosing, entity, environment, evidence, exercise, exist, February, Framework, Holocom, impairment, influence, investee, lease, leasing, modify, narrative, objectively, prospectively, realized, recording, recoverable, refundable, representation, request, requirement, retrospectively, taxable, temporary, transmitted, transparency, unpaid, unrealized, verified, weight
Financial reports
10-Q
2021 Q1
Quarterly report
5 May 21
10-KT
2020 FY
Filing
2 Mar 21
10-Q
2021 Q2
Quarterly report
29 Dec 20
10-Q
2021 Q1
Quarterly report
15 Oct 20
10-K
2020 FY
Annual report
24 Aug 20
10-Q
2020 Q3
Quarterly report
8 Apr 20
10-Q
2020 Q2
Quarterly report
14 Jan 20
10-Q
2020 Q1
Quarterly report
11 Oct 19
10-K
2019 FY
Annual report
29 Aug 19
10-Q
2019 Q3
Quarterly report
15 Apr 19
Current reports
8-K
Mosaic ImmunoEngineering Inc. Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors
15 Jun 21
8-K
Entry into a Material Definitive Agreement
10 May 21
8-K
Amendments to Articles of Incorporation or Bylaws
30 Dec 20
8-K
Material Modifications to Rights of Security Holders
1 Dec 20
8-K/A
Departure of Directors or Certain Officers
19 Nov 20
8-K/A
Index to Financial Statements
14 Oct 20
8-K
Patriot Scientific Corporation and Mosaic ImmunoEngineering Inc. Enter into Definitive Merger Agreement
25 Aug 20
8-K
Departure of Directors or Certain Officers
4 Oct 19
8-K
Entry into a Material Definitive Agreement
15 Apr 19
8-K
Departure of Directors or Certain Officers
5 Apr 19
Registration and prospectus
S-8
Registration of securities for employees
9 Mar 21
S-3/A
Shelf registration (amended)
21 Jan 21
S-3
Shelf registration
10 Dec 20
D
$3.75K in options / securities to be acquired, sold $3.75K, 1 investor
25 Jan 10
S-8
Registration of securities for employees
1 Apr 09
S-8
Registration of securities for employees
27 Mar 08
POS AM
Prospectus update (post-effective amendment)
25 Dec 07
SB-2/A
Registration of securities for small business issuer (amended)
1 Apr 07
SB-2/A
Registration of securities for small business issuer (amended)
20 Mar 07
SB-2/A
Registration of securities for small business issuer (amended)
27 Feb 07
Proxies
DEF 14C
Information statement
25 Jun 21
PRE 14C
Preliminary information
15 Jun 21
DEF 14C
Information statement
2 Nov 20
PRE 14C
Preliminary information
23 Oct 20
DEFA14A
Additional proxy soliciting materials
17 Apr 18
DEF 14A
Definitive proxy
17 Apr 18
DEF 14A
Definitive proxy
14 Mar 17
DEF 14A
Definitive proxy
17 Mar 16
PRE 14A
Preliminary proxy
7 Mar 16
DEF 14A
Definitive proxy
8 Mar 15
Other
EFFECT
Notice of effectiveness
1 Feb 21
CORRESP
Correspondence with SEC
24 Jan 21
CORRESP
Correspondence with SEC
20 Jan 21
UPLOAD
Letter from SEC
20 Dec 20
CT ORDER
Confidential treatment order
25 Sep 16
CT ORDER
Confidential treatment order
4 Jan 15
CT ORDER
Confidential treatment order
15 Sep 14
CT ORDER
Confidential treatment order
13 Feb 13
NO ACT
No action letter
17 Oct 10
NO ACT
No action letter
28 Sep 10
Ownership
3
Mosaic ImmunoEngineering / ROBERT BAFFI ownership change
16 Jul 21
4
Mosaic ImmunoEngineering / ROBERT L GARNICK ownership change
10 May 21
4
Mosaic ImmunoEngineering / GLORIA FELCYN ownership change
10 May 21
4
Mosaic ImmunoEngineering / Nicole Franziska Steinmetz ownership change
30 Apr 21
4
Mosaic ImmunoEngineering / Nicole Franziska Steinmetz ownership change
29 Jan 21
4
Mosaic ImmunoEngineering / PAUL J LYTLE ownership change
29 Jan 21
4
Mosaic ImmunoEngineering / STEVEN W KING ownership change
29 Jan 21
4
Mosaic ImmunoEngineering / ROBERT L GARNICK ownership change
29 Jan 21
4
Mosaic ImmunoEngineering / GLORIA FELCYN ownership change
18 Dec 20
4
Mosaic ImmunoEngineering / PAUL J LYTLE ownership change
16 Dec 20